NCT06474520View on ClinicalTrials.gov

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

July 31, 2029

Study Completion Date

December 31, 2029

Conditions
Idiopathic Inflammatory Demyelinating DiseaseMultiple SclerosisNeuromyelitis Optica Spectrum DisorderMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseAcute Disseminated Encephalomyelitis
Interventions
DRUG

Calculus bovis sativus (CBS)

Subjects will orally receive 100mg CBS per day from day 1 to day 84.

Trial Locations (1)

430000

RECRUITING

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Jianmin Pharmaceutical Group Co., LTD.

INDUSTRY

lead

Tongji Hospital

OTHER